Literature DB >> 2200961

Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum.

R G Ridley1, B Takacs, H W Lahm, C J Delves, M Goman, U Certa, H Matile, G R Woollett, J G Scaife.   

Abstract

We have recently demonstrated that a non-polymorphic rhoptry antigen, RAP-1 (rhoptry associated protein-1), which is recognised by human immune serum, can successfully protect Saimiri monkeys from a lethal infection of Plasmodium falciparum malaria. In this report we further characterise the antigen, which consists of four major proteins of 80, 65, 42 and 40 kDa and two minor proteins of 77 and 70 kDa, and present the antigen's gene sequence. Monoclonal antibody evidence, autocatalytic processing and immunological cross-reactivity suggest that all components of this antigen are derived from the same precursor protein. The antigen is lipophilic, and disulphide bonding plays an important role in its structure. We discuss the structure and function of RAP-1 in the light of its deduced amino acid sequence and consider the relationship of this antigen to other rhoptry antigens of similar subunit size and composition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2200961     DOI: 10.1016/0166-6851(90)90103-s

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  26 in total

1.  Interaction of HLA and age on levels of antibody to Plasmodium falciparum rhoptry-associated proteins 1 and 2.

Authors:  A Johnson; R Leke; L Harun; C Ginsberg; J Ngogang; A Stowers; A Saul; I A Quakyi
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum.

Authors:  D L Baldi; K T Andrews; R F Waller; D S Roos; R F Howard; B S Crabb; A F Cowman
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  Placental malaria diminishes development of antibody responses to Plasmodium falciparum epitopes in infants residing in an area of western Kenya where P. falciparum is endemic.

Authors:  Phillip Cullison Bonner; Zhiyong Zhou; Lisa B Mirel; John G Ayisi; Ya Ping Shi; Anna M van Eijk; Juliana A Otieno; Bernard L Nahlen; Richard W Steketee; Venkatachalam Udhayakumar
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

4.  In vitro biosynthesis and in vivo processing of the major microneme antigen of Sarcocystis muris cyst merozoites.

Authors:  H Klein; H Mehlhorn; W Rüger
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

5.  Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease.

Authors:  Natalie C Silmon de Monerri; Helen R Flynn; Marta G Campos; Fiona Hackett; Konstantinos Koussis; Chrislaine Withers-Martinez; J Mark Skehel; Michael J Blackman
Journal:  Infect Immun       Date:  2011-01-10       Impact factor: 3.441

6.  Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum.

Authors:  A A Escalante; A A Lal; F J Ayala
Journal:  Genetics       Date:  1998-05       Impact factor: 4.562

7.  Assessment of the humoral immune response against Plasmodium falciparum rhoptry-associated proteins 1 and 2.

Authors:  A Stowers; D Taylor; N Prescott; Q Cheng; J Cooper; A Saul
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

Review 8.  Cell invasion by the vertebrate stages of Plasmodium.

Authors:  P Sinnis; B K Sim
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

9.  Reactivity profile of human anti-82-kilodalton rhoptry protein antibodies generated during natural infection with Plasmodium falciparum.

Authors:  R F Howard; J B Jensen; H L Franklin
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

10.  Identification of a vaccine candidate antigen, PfMAg-1, from Plasmodium falciparum with monoclonal antibody M26-32.

Authors:  Yu-Hui Gao; Hui-Liang Li; Yan Lu; Fang-Ming Gao; Ya-Hui Lin; Hong-Chang Zhou; Lian-Hui Zhang; Heng Wang
Journal:  Parasitol Res       Date:  2009-09-24       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.